Tweet
J Formos Med Assoc. The receptor binding domain of MERS-CoV: The dawn of vaccine and treatment development
[Source: ScienceDirect, full page: (LINK). Abstract, edited.]
Journal of the Formosan Medical Association, Available online 14 December 2013 - In Press, Corrected Proof
Review article
The receptor binding domain of MERS-CoV: The dawn of vaccine and treatment development <SUP>☆</SUP>
<SUP></SUP>
Nan Zhou<SUP>a</SUP>, Yun Zhang<SUP>a</SUP>, Jin-Chun Zhang, Ling Feng, Jin-Ku Bao
School of Life Sciences & Key Laboratory of Bio-resources, Ministry of Education, Sichuan University, Chengdu 610064, China
Received 15 September 2013 / Revised 20 October 2013 / Accepted 13 November 2013 / Available online 14 December 2013
Abstract
The newly emerged Middle East respiratory syndrome coronavirus (MERS-CoV) is becoming another ?SARS-like? threat to the world. It has an extremely high death rate (∼50%) as there is no vaccine or efficient therapeutics. The identification of the structures of both the MERS-CoV receptor binding domain (RBD) and its complex with dipeptidyl peptidase 4 (DPP4), raises the hope of alleviating this currently severe situation. In this review, we examined the molecular basis of the RBD-receptor interaction to outline why/how could we use MERS-CoV RBD to develop vaccines and antiviral drugs.
Keywords: coronavirus; drug design; Middle East; vaccines
_____
☆Conflicts of interest: All authors have no conflicts of interest to declare.
Corresponding author. No. 29, Wangjiang Road, School of Life Sciences & Key Laboratory of Bio-resources, Ministry of Education, Sichuan University, Chengdu 610064, China.
a) These authors contributed equally to this work.
Copyright ? 2013 Published by Elsevier (Singapore) Pte Ltd.
Note to users: Corrected proofs are Articles in Press that contain the authors' corrections. Final citation details, e.g., volume/issue number, publication year and page numbers, still need to be added and the text might change before final publication.
Although corrected proofs do not have all bibliographic details available yet, they can already be cited using the year of online publication and the DOI , as follows: author(s), article title, journal (year), DOI. Please consult the journal's reference style for the exact appearance of these elements, abbreviation of journal names and use of punctuation.
When the final article is assigned to an issue of the journal, the Article in Press version will be removed and the final version will appear in the associated published issue of the journal. The date the article was first made available online will be carried over.
-
--------
Journal of the Formosan Medical Association, Available online 14 December 2013 - In Press, Corrected Proof
Review article
The receptor binding domain of MERS-CoV: The dawn of vaccine and treatment development <SUP>☆</SUP>
<SUP></SUP>
Nan Zhou<SUP>a</SUP>, Yun Zhang<SUP>a</SUP>, Jin-Chun Zhang, Ling Feng, Jin-Ku Bao
School of Life Sciences & Key Laboratory of Bio-resources, Ministry of Education, Sichuan University, Chengdu 610064, China
Received 15 September 2013 / Revised 20 October 2013 / Accepted 13 November 2013 / Available online 14 December 2013
Abstract
The newly emerged Middle East respiratory syndrome coronavirus (MERS-CoV) is becoming another ?SARS-like? threat to the world. It has an extremely high death rate (∼50%) as there is no vaccine or efficient therapeutics. The identification of the structures of both the MERS-CoV receptor binding domain (RBD) and its complex with dipeptidyl peptidase 4 (DPP4), raises the hope of alleviating this currently severe situation. In this review, we examined the molecular basis of the RBD-receptor interaction to outline why/how could we use MERS-CoV RBD to develop vaccines and antiviral drugs.
Keywords: coronavirus; drug design; Middle East; vaccines
_____
☆Conflicts of interest: All authors have no conflicts of interest to declare.
Corresponding author. No. 29, Wangjiang Road, School of Life Sciences & Key Laboratory of Bio-resources, Ministry of Education, Sichuan University, Chengdu 610064, China.
a) These authors contributed equally to this work.
Copyright ? 2013 Published by Elsevier (Singapore) Pte Ltd.
Note to users: Corrected proofs are Articles in Press that contain the authors' corrections. Final citation details, e.g., volume/issue number, publication year and page numbers, still need to be added and the text might change before final publication.
Although corrected proofs do not have all bibliographic details available yet, they can already be cited using the year of online publication and the DOI , as follows: author(s), article title, journal (year), DOI. Please consult the journal's reference style for the exact appearance of these elements, abbreviation of journal names and use of punctuation.
When the final article is assigned to an issue of the journal, the Article in Press version will be removed and the final version will appear in the associated published issue of the journal. The date the article was first made available online will be carried over.
-
--------